Pediatric Vouchers Can Have Heavy Adult Involvement, FDA Says
Executive Summary
Draft guidance says sponsors remain eligible for rare pediatric disease priority review voucher even if they enroll also adults in clinical trials.
You may also be interested in...
What Is A Rare Pediatric Disease? US FDA's Orphan Products Office Hopes To Update Guidance On Definition
The Office of Pediatric Therapeutics is working with the Office of Orphan Products Development to make rare pediatric disease determinations, which can help sponsors obtain a priority review voucher.
Priority Review Weirdness: Tropical Voucher Sells For More; Owner Says It’s Worth Less
Knight Therapeutics says a rare pediatric disease voucher is more valuable than its tropical disease voucher despite the sale price.
Ebola Drugs Take Center Stage In Review Voucher Bill, But Real Value May Be Harmonization
Along with adding Ebola to list of disease treatments eligible for tropical disease priority review voucher, bill moving through Congress would cut notification time required before redemption.